Cardiff Oncology, Inc.
NASDAQ:CRDFBiotechnology
+$0.03 today
- Market cap
- $65.27M
- Beta
- 1.38
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.65
Volume 0.86M
Average 1.05M
CRDF Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Cardiff Oncology, Inc.NASDAQ: CRDF
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $41K fell 62.4% year over year, behind the -10.7% change in trailing-twelve-month revenue. Sequentially, it fell 83.1% from the prior quarter. Over 3 fiscal years it compounded at +15.4% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $327.43K (-44.8%) for the fiscal year ending Dec 2026, a slowdown from the -13.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $41K-83.1% QoQ
- Last fiscal yearDec 2025
- $593K-13.2% YoY
- LTMMar 2026
- $525K-10.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -62.4% | -48.1% | +14.3 pp |
| 1 year | -13.2% | -44.8% | -31.6 pp |
| 3-year CAGR | +15.4% | -21.4% | -36.8 pp |
| 5-year CAGR | +249.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 593K USD
- Year-over-year change
- -13.2%
- 4-year CAGR
- +13.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 593K | -13.2% |
| FY2024 | 2024-12-31 | 683K | +40.0% |
| FY2023 | 2023-12-31 | 488K | +26.4% |
| FY2022 | 2022-12-31 | 386K | +7.5% |
| FY2021 | 2021-12-31 | 359K | — |
Revenue vs competitors
How CRDF compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -10.7% is the 2nd highest of 4, against a peer median of -77.9%.
- Over three fiscal years its annual growth of +15.4% compares with a peer median of -48.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $3.17M USD | +164.1% | — | |
| FY2025 | €2.79M EUR | -77.9% | -63.6% | |
| LTM Mar 2026 | $1.78M USD | — | -32.4% | |
| LTM Mar 2026 | $525K USD | -10.7% | +15.4% | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | CHF 0 CHF | -100.0% | — | |
| LTM Mar 2026 | $0 USD | — | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $0 USD | — | — |
| Peer median (excluding CRDF) | — | -77.9% | -48.0% | |
Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 359K | 386K | 488K | 683K | 593K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 359K | 386K | 488K | 683K | 593K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 17.38M | 27.11M | 32.86M | 36.85M | 35.33M |
| Selling, General & Admin | 11.84M | 13.18M | 13.04M | 12.48M | 14.22M |
| Operating Expenses | 29.21M | 40.29M | 45.9M | 49.33M | 49.55M |
| Depreciation & Amortization | 451K | 236K | 398K | 404K | 904K |
| EBITDA | (27.84M) | (38.47M) | (41.04M) | (45.03M) | (44.95M) |
| EBITDA Margin | -7754.9% | -9965.8% | -8410.5% | -6592.5% | -7579.6% |
| Operating Income | (28.86M) | (39.9M) | (45.41M) | (48.65M) | (48.96M) |
| Operating Margin | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Interest Income | 264K | 1.58M | 4.07M | 3.26M | 3.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 564K | 1.2M | 3.97M | 3.22M | 3.11M |
| Income Before Tax | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Pre-Tax Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (28.29M) | (38.7M) | (41.44M) | (45.43M) | (45.85M) |
| Net Margin | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (Basic) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| EPS (Diluted) | (0.73) | (0.89) | (0.93) | (0.95) | (0.69) |
| Weighted Avg Shares | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
| Weighted Avg Shares (Diluted) | 39.03M | 43.6M | 44.68M | 47.65M | 66.84M |
Cardiff Oncology, Inc.
NASDAQ:CRDF
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.